Cyclica is a Toronto-based, globally recognized biotechnology company that leverages artificial intelligence and computational biophysics to reshape the drug discovery process.

Cyclica’s proprietary structure-based and AI-augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights. Taken together Ligand Design and Ligand Express design advanced lead-like molecules that minimize unwanted off-target effects, while providing a holistic understanding of a molecule’s activity through integrated systems biology and structural pharmacogenomics.

All taken together, Ligand Design and Ligand Express offer a powerful end to end AI-augmented drug discovery platform for the design of advanced, chemically novel lead-like molecules that simultaneously prioritizes compounds based on their polypharmacological profile, effectively minimizing undesirable off-target effects. Our differentiated platform opens new opportunities for drug discovery, including multi-targeted and multi-objective drug design, lead optimization, ADMET-property prediction, target deconvolution, and drug repurposing.

By doing more with artificial intelligence, Cyclica aims to revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process, and develop medicines with greater precision.